Developing the first trillion dollar family of drugs, membrane active immunomodulators (MAIMS).
BTNS is a small, woman owned drug development company based in San Antonio, Texas. BTNS is developing a newly discovered class of therapeutic agents, MAIMS, that change the ways that biological molecules interact at cellular membranes. MAIMS thereby control inter-cellular signaling by controlling transmembrane signal transduction. Applications include cancer, autoimmune diseases, biodefense, ionizing radiation injury and infectious disease.